Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
IP Bevacizumab for Malignant Ascites in Ovarian Cancer
NCT01838538Phase 2Unknown
- Sponsor
- Chinese PLA General Hospital
- Start
- Jun 2011
- Primary completion
- Jun 2013
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial of bevacizumab in ovarian cancer (2 arms), sponsored by Chinese PLA General Hospital. Primary endpoint: Objective Response Rate at 24 months. Status: unknown.
02
Drugs
bevacizumab
03
Conditions
ovarian cancer
Beyond the preview
Go deeper on NCT01838538.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01838538.